First Tracks Biotherapeutics (NASDAQ:TRAX) Rating Increased to Strong-Buy at Wells Fargo & Company

Wells Fargo & Company upgraded shares of First Tracks Biotherapeutics (NASDAQ:TRAX) to a strong-buy rating in a report issued on Monday,Zacks.com reports.

A number of other research firms have also recently weighed in on TRAX. Leerink Partners assumed coverage on First Tracks Biotherapeutics in a research note on Friday, April 24th. They issued an “outperform” rating and a $46.00 price target on the stock. Zacks Research upgraded First Tracks Biotherapeutics to a “hold” rating in a research note on Monday, April 27th. Wall Street Zen upgraded First Tracks Biotherapeutics to a “hold” rating in a research note on Saturday, May 2nd. Barclays assumed coverage on First Tracks Biotherapeutics in a research note on Wednesday, April 22nd. They issued an “overweight” rating and a $40.00 price target on the stock. Finally, Wedbush assumed coverage on First Tracks Biotherapeutics in a research note on Friday, April 24th. They issued an “outperform” rating and a $30.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $38.25.

First Tracks Biotherapeutics Stock Down 5.1%

First Tracks Biotherapeutics stock opened at $15.75 on Monday. First Tracks Biotherapeutics has a 1-year low of $14.72 and a 1-year high of $26.80.